Antigen Binding Articles & Analysis
29 articles found
In recent years, the field of antibody drug design has become increasingly significant in the realm of therapeutic development, driven by the need for more effective and targeted treatments for various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibodies, which are proteins produced by the immune system, have the ability to specifically recognize and bind to ...
Therapeutic monoclonal antibodies (mAbs) are a class of antibody drugs that are highly uniform and have pharmacological effects against a single epitope obtained through molecular biology. In the process of new drug development, the study of pharmacokinetics is of great significance. The result can be used to guide the screening and development of drugs, and support the evaluation of their ...
When we talk about antibody sequencing, we often think of issues related to disease treatment and improving human health. Nanobody sequencing provides us with a more precise and efficient solution. Nanobodies, also known as single-domain antibodies, are antibodies composed of a single functional domain. They have the advantages of small size, high stability, and good penetration, and therefore ...
Monoclonal antibodies are highly specific biological molecules that are crucial in many areas like disease diagnosis, treatment, and biomarker discovery. They can trigger an immune response in the human body by recognizing and binding to specific antigens, thereby combating pathogens. However, to develop monoclonal antibodies with high specificity and affinity, sequencing of the antibody's ...
Biopharmaceuticals and personalized medicine are hot fields in the development of the pharmaceutical industry today. Proteins, peptides, and antibodies are important molecules in the body and are important objects of research in biopharmaceuticals and personalized medicine. With the continuous advancement of protein, peptide, and antibody sequencing technology, they are playing an increasingly ...
Antibodies are an essential part of our immune system, capable of recognizing foreign molecules (antigens) and helping to eliminate them. Antibodies have a high degree of target specificity, affinity, and safety, and have been widely used in the treatment, diagnosis, and prevention of many major diseases. They are currently a focus in new drug development. The design of antibody drugs is a ...
The Constant Region of an antibody is a part of the immunoglobulin (antibody) molecule, responsible for stabilizing the structure of the antibody to execute its specific immune function. The constant region of an antibody is usually at the bottom of the molecule, close to the tail of the antibody, corresponding to the variable region of the antibody, which is responsible for recognizing and ...
What is a Nanobody?Nanobodies are the smallest functional single-domain antibodies known to be able to stably bind to antigens, and have unique structural and functional advantages. The molecular weight of nanobodies is only 12-15 kDa, which retains the antigen binding ability of traditional antibodies. However, nanobodies have higher solubility and stability, and have unique advantages in ...
Introduction Chemotherapy with anti-tumor agents is currently one of the most important systemic treatments for cancer. However, direct treatment with drugs lacks specificity and sensitivity and tends to attack normal cells indiscriminately, resulting in side effects. Liposomes, as drug carriers, provide a superior solution for maintaining or enhancing the efficacy of chemotherapy while reducing ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, has announced the launch of its innovative line of Chromogenic Substrates for immunohistochemistry (IHC). These cutting-edge substrates offer superior signal sensitivity, long-term storage stability, enhanced safety, and user-friendliness, empowering researchers to unlock deeper insights into ...
Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. So far, a total of 15 ADC drugs have been approved worldwide, of which the FDA has approved 13 ADCs for various cancers, including Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Lumoxiti®, Polivy®, Padcev®, Enhertu ®, Trodelvy® and Blenrep®. As ...
With the rapid development of antibody-drug conjugate (ADC), more and more companies have entered the field of ADC research and development, and various types of ADC technologies and branches have emerged. Bispecific antibody conjugates (BsAb ADCs) are one of the emerging new technologies. The high specificity of bispecific antibodies enables more precise targeting of tumor cells. On the other ...
In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell's own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from PROTAC, various targeted protein degradation (TPD) strategies are emerging, involving molecular glue, Autophagy-Targeting Chimera (AUTEC), Autophagosome Tethering Compound ...
Molecular docking, a critical component of structure-based virtual screening, plays a pivotal role in the field of drug design by predicting the binding interactions between small molecules and proteins. This article explores the various approaches, software tools, and techniques employed in molecular docking and highlights their potential in accelerating drug discovery. The Importance of ...
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
Feline herpesvirus type 1 (FHV-1) can cause acute and highly contagious infectious diseases in cats, namely feline infectious rhinotracheitis. In 1958, FHV-1 was isolated and identified for the first time from kittens suffering from respiratory diseases in the United States by Crandell et al. Clinical manifestations include keratoconjunctivitis, upper respiratory tract infection and miscarriage, ...
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently ...
A research team's latest study shows that two human antibodies can simultaneously target two Ebola viruses: Ebola and Sudan. These two species have caused the largest and deadliest outbreaks. The new report suggests that researchers could combine these two potent antibodies to create an effective antiviral therapy. The work is published in Cell in the paper, “Asymmetric and ...
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with DNA.PBD dimers are about 50-100 times more potent than conventional ...
Kadcyla and second-generation non-cleavable linkers Alternative linker design methodologies are still under development. Immunogen discovered a very powerful ADC by an accidental discovery. The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in ...